Hello, this is the one and only Nana. This morning was really FOGGY! I didn’t expect this at all. I am still not used to ...

The Mohawk Valley Hometown Heroes banners for veterans program is expanding to more Oneida County communities and will begin ...

The Classical High School gym has a leaky roof and rickety bleachers but it pulses with Purple pride after a banner year.

Banner Corporation (NASDAQ:BANR) Q4 2024 Earnings Call Transcript January 23, 2025 Operator: Hello, everyone, and welcome to the Banner Corporation's Fourth Quarter 2024 Conference Call and Webcast.

Good morning and Happy New Year, everyone. I would also like to welcome you to the fourth-quarter and full-year 2024 earnings call for Banner Corporation. Joining me on the call today is Rob ...

Please go ahead. Thank you, Marie. Good morning and Happy New Year, everyone. I would also like to welcome you to the fourth-quarter and full-year 2024 earnings call for Banner Corporation. Joining me ...

Non-Interest Expense: Increased by $3.2 million from the prior quarter. Banner Corp (NASDAQ:BANR) reported a net profit of $46.4 million or $1.34 per diluted share for Q4 2024, an increase from $1.24 ...

Evan Zimmer has been writing about finance for years. After graduating with a journalism degree from SUNY Oswego, he wrote credit card content for Credit Card Insider (now Money Tips) before ...

Other items that the PCPL board approved was the 2025 wage schedule along with reconciling funds from the 2024 budget. The board also also approved their annual agreement with the Hammer & Swigart ...

Florida football coach Billy Napier was rewarded for leading the Florida Gators to their first winning season since 2020. Napier earned a $100,000 bonus for leading UF to more than six wins and a ...

Based on the one-year price targets offered by 6 analysts, the average target price for Banner Corp (NASDAQ:BANR) is $74.00, with a high estimate of $82.00 and a low estimate of $65.00.

The biosimilar landscape continues to expand, with 2024 delivering a wave of exciting approvals across multiple therapeutic areas. Last year alone saw the FDA green light some firsts for biosimilars ...